BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26799514)

  • 1. NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer.
    Silva MP; Barros-Silva JD; Vieira J; Lisboa S; Torres L; Correia C; Vieira-Coimbra M; Martins AT; Jerónimo C; Henrique R; Paulo P; Teixeira MR
    Genes Chromosomes Cancer; 2016 Apr; 55(4):365-74. PubMed ID: 26799514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.
    Barros-Silva JD; Ribeiro FR; Rodrigues A; Cruz R; Martins AT; Jerónimo C; Henrique R; Teixeira MR
    Genes Chromosomes Cancer; 2011 Aug; 50(8):662-71. PubMed ID: 21584900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
    Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
    Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
    El Gammal AT; Brüchmann M; Zustin J; Isbarn H; Hellwinkel OJ; Köllermann J; Sauter G; Simon R; Wilczak W; Schwarz J; Bokemeyer C; Brümmendorf TH; Izbicki JR; Yekebas E; Fisch M; Huland H; Graefen M; Schlomm T
    Clin Cancer Res; 2010 Jan; 16(1):56-64. PubMed ID: 20028754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer.
    Reiter RE; Sato I; Thomas G; Qian J; Gu Z; Watabe T; Loda M; Jenkins RB
    Genes Chromosomes Cancer; 2000 Jan; 27(1):95-103. PubMed ID: 10564591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer.
    van Duin M; van Marion R; Vissers K; Watson JE; van Weerden WM; Schröder FH; Hop WC; van der Kwast TH; Collins C; van Dekken H
    Genes Chromosomes Cancer; 2005 Dec; 44(4):438-49. PubMed ID: 16130124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
    Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
    Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
    Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
    Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
    Jenkins RB; Qian J; Lieber MM; Bostwick DG
    Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes.
    Jin Y; Möller E; Nord KH; Mandahl N; Von Steyern FV; Domanski HA; Mariño-Enríquez A; Magnusson L; Nilsson J; Sciot R; Fletcher CD; Debiec-Rychter M; Mertens F
    Genes Chromosomes Cancer; 2012 May; 51(5):510-20. PubMed ID: 22337624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG.
    Silva MP; Barros-Silva JD; Ersvær E; Kildal W; Hveem TS; Pradhan M; Vieira J; Teixeira MR; Danielsen HE
    Transl Oncol; 2016 Dec; 9(6):575-582. PubMed ID: 27916292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications.
    Van Den Berg C; Guan XY; Von Hoff D; Jenkins R; Bittner ; Griffin C; Kallioniemi O; Visakorpi ; McGill ; Herath J
    Clin Cancer Res; 1995 Jan; 1(1):11-8. PubMed ID: 9815882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects.
    Ribeiro FR; Jerónimo C; Henrique R; Fonseca D; Oliveira J; Lothe RA; Teixeira MR
    Clin Cancer Res; 2006 Jul; 12(13):3961-70. PubMed ID: 16818693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization.
    Sauter G; Carroll P; Moch H; Kallioniemi A; Kerschmann R; Narayan P; Mihatsch MJ; Waldman FM
    Am J Pathol; 1995 May; 146(5):1131-9. PubMed ID: 7747807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
    Sato H; Minei S; Hachiya T; Yoshida T; Takimoto Y
    Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma.
    Mosquera JM; Sboner A; Zhang L; Kitabayashi N; Chen CL; Sung YS; Wexler LH; LaQuaglia MP; Edelman M; Sreekantaiah C; Rubin MA; Antonescu CR
    Genes Chromosomes Cancer; 2013 Jun; 52(6):538-50. PubMed ID: 23463663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.
    Sato K; Qian J; Slezak JM; Lieber MM; Bostwick DG; Bergstralh EJ; Jenkins RB
    J Natl Cancer Inst; 1999 Sep; 91(18):1574-80. PubMed ID: 10491435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic aberrations in prostate cancer by microarray analysis.
    Saramäki OR; Porkka KP; Vessella RL; Visakorpi T
    Int J Cancer; 2006 Sep; 119(6):1322-9. PubMed ID: 16642477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic utility of NCOA2 fluorescence in situ hybridization and Stat6 immunohistochemistry staining for soft tissue angiofibroma and morphologically similar fibrovascular tumors.
    Sugita S; Aoyama T; Kondo K; Keira Y; Ogino J; Nakanishi K; Kaya M; Emori M; Tsukahara T; Nakajima H; Takagi M; Hasegawa T
    Hum Pathol; 2014 Aug; 45(8):1588-96. PubMed ID: 24856853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.